Commercial Insight: Depression -Atypical lifecycle management strategy rejuvenates depression market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-06-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.


Scope

  • This report focuses on the leading pharmacotherapies used to treat depression with sales and volume country- and indication-specific forecasts to 2016
  • Assessment of current and future opportunities and threats in the depression market across the seven major pharmaceutical markets
  • Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
  • Lifecycle management case studies show how previously successful strategies should be applied in today's market


    • Report Highlights
    Sales of atypical antipsychotics in depression are set to be stimulated by anticipated positive clinical trial data investigating the use of Seroquel (quetiapine) in this indication. Datamonitor forecasts peak class level seven major market sales of $1.43 billion in 2008, followed by a decline due to competition from pipeline drugs and generics.

    Timing of launch of Wyeth's reformulation Pristiq (desvenlafaxine) would appear to be optimal. However, no evidence exists to indicate that it is an improvement over the parent compound Effexor (venlafaxine). By focusing Pristiq on a niche cohort of depressed patients, Wyeth has done enough to diversify Pristiq to ensure moderate success.

    The introduction of newer generation antidepressants such as the SNRIs Effexor and Cymbalta (duloxetine) and the SSRI Lexapro (escitalopram) into the Japanese depression market will drive its value considerably, resulting in a 52% increase by 2012.


    Reasons to Purchase

  • Assess the impact of events such as patent expiries and new product launches on the depression-specific sales of key marketed brands
  • Quantify the future size of the depression market, in terms of volume and value, in each of the seven major markets
  • Identify key lifecycle management strategies that can ensure growth in the competitive depression market

    • Table of Contents

    Other users found this report page using the following search terms: depression Antidepressants major depression pristiq what desvenlafaxine uk trials clinical failures cr ssri investors

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.